Trump unveils phased tariffs on generic drugs to reshore pharmaceutical manufacturing

Published Jul 22, 03:31 AM UTC

President Donald Trump announced a phased tariff regime on imported generic drugs, announced via Truth Social on July 21, 2026. The policy grants a two-year tariff-free window starting August 1, 2026, followed by a 100% tariff in August 2028, escalating to 200% thereafter for non-compliant importers. Trump framed the escalation as a penalty for companies failing to invest in U.S. plants, aiming to reshore generic pharmaceutical production. This extends earlier April 2026 actions under Section 232 that imposed 100% tariffs on patented drugs and APIs unless manufacturers agreed to domestic production or Most Favored Nation pricing. The policy has major implications for India, which supplies nearly 50% of U.S. generic medicines by volume, with firms like Sun Pharma, Dr. Reddy's, Cipla, Lupin, and Aurobindo Pharma exposed. Analysts warn of long-term pressure, especially given upstream reliance on Chinese APIs.